MIRA Pharmaceuticals (NASDAQ:MIRA) Releases Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) released its quarterly earnings data on Friday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.14, Zacks reports.

MIRA Pharmaceuticals Stock Performance

NASDAQ MIRA traded down $0.04 during trading on Friday, reaching $1.06. 81,979 shares of the company’s stock were exchanged, compared to its average volume of 316,854. MIRA Pharmaceuticals has a 1 year low of $0.51 and a 1 year high of $5.01. The stock has a market cap of $17.55 million, a P/E ratio of -1.89 and a beta of 2.31. The company has a 50 day moving average price of $1.12 and a two-hundred day moving average price of $1.23.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.